Anavex gains after seeking EU marketing nod for Alzheimer’s drug
Anavex Life Sciences (NASDAQ:AVXL) traded ~10% higher in the premarket after the company said it submitted a marketing ...
Nature10d
New schizophrenia drug could treat Alzheimer’s disease
Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...
BioSpace12d
AbbVie’s Setback Gives BMS Commanding Lead in Schizophrenia Space
With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...
healthday16d
FDA Approves Cobenfy for Adults With Schizophrenia
The U.S. Food and Drug Administration has approved Cobenfy (xanomeline and trospium chloride), a first-in-class musc ...
BioWorld17d
Vanderbilt University discovers new muscarinic M4 receptor PAMs
Vanderbilt University has described muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, sleep disorders ...
pharmaphorum3y
Cerevel soars on first data for muscarinic schizophrenia drug
The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...
Nature5y
Tuning muscarinic receptor signalling
The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...